• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Rocket Pharmaceuticals, Inc. - Common Stock (NQ:RCKT)

2.600 +0.120 (+4.84%)
Delayed Quote Updated: 12:44 PM EDT, Oct 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,328,165
Open 2.450
Bid (Size) 2.600 (2,500)
Ask (Size) 2.610 (2,700)
Prev. Close 2.480
Today's Range 2.420 - 2.640
52wk Range 2.460 - 5.450
Shares Outstanding 65,837,894
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar
Today 9:36 EDT
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Rocket Pharmaceuticals Details RP-A501 Pivotal Plan After Safety Reset ↗
October 06, 2026
Rocket Pharmaceuticals (NASDAQ:RCKT) outlined updated clinical, regulatory and commercial plans for its investigational gene therapy RP-A501 in Danon disease, reporting longer-term Phase I findings,... 
Via MarketBeat

Performance

52-Week Range 52.3% below 52-week high
2.600
2.4652W Low 5.4552W High
1 Week 5.3% below 1-week high
2.461W Low 2.751W High

Rocket Pharmaceuticals, Inc. - Common Stock (RCKT) traded between $2.46 and $5.45 over the past 52 weeks and last traded at $2.60, 52.3% below its 52-week high. Over the past week it ranged between $2.46 and $2.75.

Past 12 Months
-1.1%
-29.9%
-36.1%
-25.3%
-24.9%
-18.2%
1W -$0.03
1M -$1.11
3M -$1.47
6M -$0.88
YTD -$0.86
1Y -$0.58

RCKT was -18.2% over the past year, -25.3% over six months, -24.9% year to date, -1.1% in the last week.

12 Months vs Market
RCKT
-18.2%
DIA
+9.4%
SPY
+15.6%
QQQ
+24.4%
IWM
+12.5%

Over the past 12 months RCKT returned -18.2% versus DIA (Dow) +9.4%, SPY (S&P 500) +15.6%, QQQ (Nasdaq 100) +24.4% and IWM (Russell 2000) +12.5%.

Volume & Liquidity 0.78× 3-mo avg
Today 1,328,165 3-mo avg 1.7M
1W
2.0M
1M
1.9M
3M
1.7M
6M
2.1M
YTD
2.5M
1Y
2.5M

RCKT most recently traded 1,328,165 shares against a 3-month average daily volume of 1.7M.

More News

Read More
News headline image
Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital
October 06, 2026
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease
September 15, 2026
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
September 03, 2026
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress
August 10, 2026
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease
August 03, 2026
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million
June 12, 2026
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
May 28, 2026
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress
May 07, 2026
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher
April 28, 2026
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA
April 02, 2026
Via MarketMinute
Topics Intellectual Property Lawsuit
News headline image
Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)
March 27, 2026
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress
February 26, 2026
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
February 23, 2026
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Rocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference
January 05, 2026
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference
November 25, 2025
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Helmerich and Payne, Invivyd, Home Depot And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
November 18, 2025
Via Benzinga
News headline image
Rocket Pharmaceuticals Inc (NASDAQ:RCKT) Posts Narrower Q3 2025 Loss, Advances Gene Therapy Pipeline ↗
November 06, 2025
Via Chartmill
News headline image
Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
November 06, 2025
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy ↗
November 04, 2025
Via Benzinga
News headline image
ROCKET ALERT: Bragar Eagel & Squire, P.C. is Investigating Rocket Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
October 23, 2025
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
FDA Acceptance Of Rocket Pharmaceuticals' Lead Gene Therapy Application Reestablishes Momentum For Stock ↗
October 14, 2025
Via Benzinga
News headline image
Domino's Pizza Posts Upbeat Results, Joins Astria Therapeutics, Albertsons Companies, Polaris And Other Big Stocks Moving Higher On Tuesday ↗
October 14, 2025
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
October 14, 2025
Via Benzinga

Frequently Asked Questions

Is Rocket Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Rocket Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Rocket Pharmaceuticals, Inc. - Common Stock trade on?
Rocket Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Rocket Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Rocket Pharmaceuticals, Inc. - Common Stock is RCKT on the Nasdaq Stock Market
What is the current price of Rocket Pharmaceuticals, Inc. - Common Stock?
The current price of Rocket Pharmaceuticals, Inc. - Common Stock is 2.600
When was Rocket Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Rocket Pharmaceuticals, Inc. - Common Stock was at 10/07/26 12:44 PM ET
What is the market capitalization of Rocket Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Rocket Pharmaceuticals, Inc. - Common Stock is 171.18M
How many shares of Rocket Pharmaceuticals, Inc. - Common Stock are outstanding?
Rocket Pharmaceuticals, Inc. - Common Stock has 171M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap